Anti-cytokine therapies in T1D: Concepts and strategies

Gerald T Nepom; Mario Ehlers; Thomas Mandrup-Poulsen

doi:10.1016/j.clim.2013.02.003

Anti-cytokine therapies in T1D: Concepts and strategies

Gerald T Nepom, Mario Ehlers, Thomas Mandrup-Poulsen

46 Citations (Scopus)

Abstract

Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.

Original language	English
Journal	Clinical Immunology
Volume	149
Issue number	3 Part A
Pages (from-to)	279-85
Number of pages	7
ISSN	1521-6616
DOIs	https://doi.org/10.1016/j.clim.2013.02.003
Publication status	Published - Dec 2013

Keywords

Antibodies, Monoclonal
Clinical Trials as Topic
Diabetes Mellitus, Type 1
Humans
Hypoglycemic Agents
Immunotherapy
Interleukin-1
Interleukin-12
Interleukin-23
Interleukin-6
T-Lymphocytes, Regulatory
Tumor Necrosis Factor-alpha

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clim.2013.02.003

Cite this

@article{36d6efb874d544c6bf6c25bdb4656ed7,

title = "Anti-cytokine therapies in T1D: Concepts and strategies",

abstract = "Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.",

keywords = "Antibodies, Monoclonal, Clinical Trials as Topic, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Immunotherapy, Interleukin-1, Interleukin-12, Interleukin-23, Interleukin-6, T-Lymphocytes, Regulatory, Tumor Necrosis Factor-alpha",

author = "Nepom, {Gerald T} and Mario Ehlers and Thomas Mandrup-Poulsen",

year = "2013",

month = dec,

doi = "10.1016/j.clim.2013.02.003",

language = "English",

volume = "149",

pages = "279--85",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press",

number = "3 Part A",

}

TY - JOUR

T1 - Anti-cytokine therapies in T1D

T2 - Concepts and strategies

AU - Nepom, Gerald T

AU - Ehlers, Mario

AU - Mandrup-Poulsen, Thomas

PY - 2013/12

Y1 - 2013/12

N2 - Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.

AB - Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.

KW - Antibodies, Monoclonal

KW - Clinical Trials as Topic

KW - Diabetes Mellitus, Type 1

KW - Humans

KW - Hypoglycemic Agents

KW - Immunotherapy

KW - Interleukin-1

KW - Interleukin-12

KW - Interleukin-23

KW - Interleukin-6

KW - T-Lymphocytes, Regulatory

KW - Tumor Necrosis Factor-alpha

U2 - 10.1016/j.clim.2013.02.003

DO - 10.1016/j.clim.2013.02.003

M3 - Journal article

C2 - 23510726

SN - 1521-6616

VL - 149

SP - 279

EP - 285

JO - Clinical Immunology

JF - Clinical Immunology

IS - 3 Part A

ER -

Anti-cytokine therapies in T1D: Concepts and strategies

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this